Ozanimod

Chemical formula: C₂₃H₂₄N₄O₃  Molecular mass: 404.47 g/mol  PubChem compound: 52938427

Therapeutic indications

Ozanimod is indicated for:

Relapsing remitting multiple sclerosis (RRMS)

Population group: only adults (18 years old or older)

Ozanimod is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Ozanimod is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Severe hepatic impairment

Hepatic failure stage IV

Active malignancies

Malignant tumour

Infection

Infectious disease

Second-degree or third degree atrioventricular (AV) block, sick sinus syndrome

at least one of
Second degree atrioventricular block
Complete atrioventricular block
Sick sinus syndrome

Immunodeficiency

Immunodeficiency

Myocardial infarction, unstable angina, stroke, transient ischaemic attack, decompensated heart failure

at least one of
Myocardial infarction
Preinfarction syndrome
CVA - Cerebrovascular accident
Temporary cerebral vascular dysfunction
Decompensated chronic heart failure
Heart failure New York Heart Assosiation Class IΙΙ
Heart failure New York Heart Assosiation Class IV

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.